Your Partner in SCA Risk Management

GDMT Takes Time. SCD Doesn’t Wait.


Protecting Against SCD Is Only Half the Story
Anchored by the ASSURE® WCD, the Cardiac Recovery System® (CRS) platform bridges the gap by pairing proven protection with insights to support recovery.
The Cardiac Recovery System platform:
- Provides insights that may be helpful in care optimization, including arrhythmia detection (VT/VF, SVT and bradyarrhythmia) and physiologic trends (heart rate and activity)
- Extends care team's reach through timely clinical alerts & rapid post-shock support
By combining proven therapy with increased visibility, the CRS platform empowers providers to protect patients and support their recovery as GDMT reaches full effect.
- Duncker D. et al. Eur Heart J. 2025;00:1–10.
- Duncker D, et al. Clin Cardiol. 2017;40(8):586-590.
The Cardiac Recovery System Platform Empowers Confident Care
Designed for Daily Life

With the most customizable fit in the category—seven sizes and two styles—the ASSURE system delivers exceptional comfort and compliance.
- Worn for more than 23 hours per day3
- Up to 87% fewer patients experiencing false alarms than competing WCD patients*3,4
*Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.
Insights to Inform Care

In real-world use, the ASSURE system identified potentially actionable cardiac events5,6:
- Detected arrhythmias in 18% of patients, leading to physician-directed clinical intervention
- VT/VF in 7% of patients, including asymptomatic events
- SVTs in 11% of patients, including AF/AFL
- Helped identify previously undiagnosed atrial fibrillation in 5.5% of patients with high stroke risk
- Recorded asymptomatic VT in 3.6% of patients, supporting further clinical review for ICD eligibility
An Extension of Your Care Team

Connected services enable timely clinical intervention and patient support.
- Heart Alert™ Services identifies and notifies providers of cardiac events that may warrant action, supporting optimization of care.
- Following a shock, the ASSURE® Assist service is designed to connect patients to the urgent support they need.
- ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS) NCT05135403, Cohort April 2024.
- Arkles, J. et al. J Interv Card Electrophyiol. 2023;66(7):1723-1728.
- Phukan A. et el. Clinical Impact of Ventricular and Supraventricular Arrhythmia Detection with a Novel Wearable Cardioverter Defibrillator. American Heart Association Scientific Sessions. Nov, 2024. Chicago, IL.
- Syed Z, et el. Initial Real-world Experience with a Novel Wearable Cardioverter Defibrillator. American Heart Association Scientific Sessions. Nov, 2024. Chicago, IL.
MKT-00162-01_B




